Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.

ABSTRACT:

Background

The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk was previously developed. This study evaluates the GEP's prognostic accuracy in an independent cohort of cutaneous melanoma patients.

Methods

This multi-center study analyzed primary melanoma tumors from 523 patients, using the GEP to classify patients as Class 1 (low risk) and Class 2 (high risk). Molecular classification was correlated to clinical outcome and assessed along with AJCC v7 staging criteria. Primary endpoints were recurrence-free (RFS) and distant metastasis-free (DMFS) survival.

Results

The 5-year RFS rates for Class 1 and Class 2 were 88% and 52%, respectively, and DMFS rate

SUBMITTER: Zager JS 

PROVIDER: S-EPMC5800282 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature